Rise in incidence of growth hormone deficiencies is the factor basically responsible for the expansion of growth hormone deficiency market. Growth hormone deficiency is amongst the disorders characterized by inappropriate secretion of the growth hormone (GH) from anterior pituitary gland, which truncates the height of children. Besides, secretion of this hormone declines with the passage of age.
The companies operating in growth hormone deficiency market are collaborating with various research institutes to explore the incorporation of investigational oral therapy that is in analogy with human growth hormone in pediatric growth hormone deficiency. They are looking toward adopting this therapy in line with the research findings that state that it increases height velocity for the children.
Growth hormone deficiency, also called pituitary dwarfism, is referred to as a condition resulting out of insufficient quantities of growth hormone in body. Those suffering from this deficiency generally have an abnormally short stature.
There has been a persistent rise in public understanding regarding application of synthetic growth hormone therapy. This human growth hormone aids in stimulating reproduction, regeneration, and growth of the humans. Development of new-fangled recombinant human growth hormones is likely of contributing to growth hormone deficiency industry growth.
As per a research article published in the Intractable & Rare Diseases Research 2018 by Xiaoxiao Cui et al., Turner Syndrome (TS) us a relatively common kind of human chromosomal aberration occurring in 1 amongst 2,500 live female births. Majority of patients are found in China.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Growth hormone deficiency may be total (pituitary gland does not produce any growth hormone) or partial (pituitary gland produces insufficient quantity of growth hormone). It is likely to occur either at the time of infancy or later during childhood. Early detection as well as treatment can help such children in reaching a normal height.
Though growth hormone deficiency does not adversely affect the child’s intelligence, he/she may have an immature appearance as compared to the peers, along with a chubby body build, underdeveloped bridge of nose, and prominent forehead.
Growth hormone deficiency ends up affecting one in close to 4,000 to 10,000 people. It could be congenital (such as caused due to genetic mutation) or acquired post-birth owing to trauma, radiation therapy, surgery, or brain tumor.
Need to diagnose growth hormone deficiency on time is thus accelerating the growth hormone deficiency market opportunities.
Research states that secretion of growth hormones falls with aging. It further states that over 30% of the elderly population has circulating growth hormone levels below the normal range.
As per the National Institutes of Health, progressive decline of growth hormone secretion amounts to 15% for every decade post 30 years of age. It also mentions that integrated measurements of the daily growth hormone secretion states that this secretion is at its peak at puberty at close to 150 µg/Kg/day, then declines to around 25 µg/Kg/day by the age of 55.
As per the WHO, the percentage of population aged 60 and above will increase from 12% to 22% between 2015 and 2050.
Need to address the concerns pertaining to growth hormone insufficiency of the aging population is thus expanding the growth hormone deficiency market size.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest growth hormone deficiency market analysis, North America dominated the growth hormone therapy landscape and the scenario is expected to remain unchanged during the forecast period. This is attributed to conducive reimbursement policies laid down by the U.S., along with well-established healthcare infrastructure.
Additionally, growing awareness regarding hormonal deficiencies is expected to bolster the growth hormone deficiency market. For example, the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP) celebrates the Children’s Growth Awareness Day for spreading awareness regarding early diagnosis as well as treatment of the growth hormone disorders.
The key players in the growth hormone deficiency market are launching new products and seeking speedy approvals to overpower the counterparts. For instance, in September 2020, Novo Nordisk received approval from the U.S. FDA for Sogroya (somapacitan). It is used for treating adults contracting growth hormone deficiency.
Novo Nordisk A/S, Pfizer Inc., Merck KGaA, Eli Lilly and Company, Novartis AG, F. Hoffmann-La Roche AG, Ipsen Pharma, Ferring Pharmaceuticals, Anhui Anke Biotechnology (Group) Co., Ltd., Zhongshan Sinobioway Hygene Biomedicine Co., Ltd., and Others are some of the key players covered in the growth hormone deficiency market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 4.3 Bn |
| Market Forecast (Value) in 2034 | US$ 7.0 Bn |
| Growth Rate (CAGR) | 4.4% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 4.3 Bn in 2023
It is projected to grow at a CAGR of 4.4% from 2024 to 2034
Growing prevalence of growth hormone deficiencies and rise in geriatric population
Hospital pharmacies segment accounted for the largest share in 2023
North America was the dominant region in 2023
Novo Nordisk A/S, Pfizer Inc., Merck KGaA, Eli Lilly and Company, Novartis AG, F. Hoffmann-La Roche AG, Ipsen Pharma, Ferring Pharmaceuticals, Anhui Anke Biotechnology (Group) Co., Ltd., Zhongshan Sinobioway Hygene Biomedicine Co., Ltd., and Others
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Growth Hormone Deficiency Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Growth Hormone Deficiency Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Growth Hormone Deficiency Market Analysis and Forecast, by Treatment Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2020-2034
6.3.1. Therapeutic Treatment
6.3.1.1. Norditropin
6.3.1.2. Genotropin
6.3.1.3. Humatrope
6.3.1.4. Saizen
6.3.1.5. Others (Omnitrope, etc.)
6.3.2. Recombinant Human Growth Hormone
6.3.3. Human Pituitary Gland Extracts
6.3.4. Surgery
6.4. Market Attractiveness, by Treatment Type
7. Global Growth Hormone Deficiency Market Analysis and Forecast, by Disease Indication
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2020-2034
7.3.1. Pediatric Growth Hormone Deficiency
7.3.2. Idiopathic Short Stature
7.3.3. Small for Gestational Age
7.3.4. Turner Syndrome
7.3.5. Adult Growth Hormone Deficiency
7.3.6. Others (Prader-Willi Syndrome, etc.)
7.3.7. 7.4 Market Attractiveness, by Disease Indication
8. Global Growth Hormone Deficiency Market Analysis and Forecast, by Route of Administration
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2020-2034
8.3.1. Subcutaneous
8.3.2. Intramuscular
8.3.3. Intravenous
8.4. Market Attractiveness, by Route of Administration
9. Global Growth Hormone Deficiency Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2020-2034
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness, by Distribution Channel
10. Global Growth Hormone Deficiency Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Growth Hormone Deficiency Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Type, 2020-2034
11.2.1. Therapeutic Treatment
11.2.1.1. Norditropin
11.2.1.2. Genotropin
11.2.1.3. Humatrope
11.2.1.4. Saizen
11.2.1.5. Others (Omnitrope, etc.)
11.2.2. Recombinant Human Growth Hormone
11.2.3. Human Pituitary Gland Extracts
11.2.4. Surgery
11.3. Market Attractiveness, by Treatment Type
11.4. Market Value Forecast, by Disease Indication, 2020-2034
11.4.1. Pediatric Growth Hormone Deficiency
11.4.2. Idiopathic Short Stature
11.4.3. Small for Gestational Age
11.4.4. Turner Syndrome
11.4.5. Adult Growth Hormone Deficiency
11.4.6. Others (Prader-Willi Syndrome, etc.)
11.5. Market Attractiveness, by Disease Indication
11.6. Market Value Forecast, by Route of Administration, 2020-2034
11.6.1. Subcutaneous
11.6.2. Intramuscular
11.6.3. Intravenous
11.7. Market Attractiveness, by Route of Administration
11.8. Market Value Forecast, by Distribution Channel, 2020-2034
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Online Pharmacies
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Treatment Type
11.11.2. By Disease Indication
11.11.3. By Route of Administration
11.11.4. By Distribution Channel
11.11.5. By Country
12. Europe Growth Hormone Deficiency Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Type, 2020-2034
12.2.1. Therapeutic Treatment
12.2.1.1. Norditropin
12.2.1.2. Genotropin
12.2.1.3. Humatrope
12.2.1.4. Saizen
12.2.1.5. Others (Omnitrope, etc.)
12.2.2. Recombinant Human Growth Hormone
12.2.3. Human Pituitary Gland Extracts
12.2.4. Surgery
12.3. Market Attractiveness, by Treatment Type
12.4. Market Value Forecast, by Disease Indication, 2020-2034
12.4.1. Pediatric Growth Hormone Deficiency
12.4.2. Idiopathic Short Stature
12.4.3. Small for Gestational Age
12.4.4. Turner Syndrome
12.4.5. Adult Growth Hormone Deficiency
12.4.6. Others (Prader-Willi Syndrome, etc.)
12.5. Market Attractiveness, by Disease Indication
12.6. Market Value Forecast, by Route of Administration, 2020-2034
12.6.1. Subcutaneous
12.6.2. Intramuscular
12.6.3. Intravenous
12.7. Market Attractiveness, by Route of Administration
12.8. Market Value Forecast, by Distribution Channel, 2020-2034
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Treatment Type
12.11.2. By Disease Indication
12.11.3. By Route of Administration
12.11.4. By Distribution Channel
12.11.5. By Country/Sub-region
13. Asia Pacific Growth Hormone Deficiency Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Type, 2020-2034
13.2.1. Therapeutic Treatment
13.2.1.1. Norditropin
13.2.1.2. Genotropin
13.2.1.3. Humatrope
13.2.1.4. Saizen
13.2.1.5. Others (Omnitrope, etc.)
13.2.2. Recombinant Human Growth Hormone
13.2.3. Human Pituitary Gland Extracts
13.2.4. Surgery
13.3. Market Attractiveness, by Treatment Type
13.4. Market Value Forecast, by Disease Indication, 2020-2034
13.4.1. Pediatric Growth Hormone Deficiency
13.4.2. Idiopathic Short Stature
13.4.3. Small for Gestational Age
13.4.4. Turner Syndrome
13.4.5. Adult Growth Hormone Deficiency
13.4.6. Others (Prader-Willi Syndrome, etc.)
13.5. Market Attractiveness, by Disease Indication
13.6. Market Value Forecast, by Route of Administration, 2020-2034
13.6.1. Subcutaneous
13.6.2. Intramuscular
13.6.3. Intravenous
13.7. Market Attractiveness, by Route of Administration
13.8. Market Value Forecast, by Distribution Channel, 2020-2034
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Treatment Type
13.11.2. By Disease Indication
13.11.3. By Route of Administration
13.11.4. By Distribution Channel
13.11.5. By Country/Sub-region
14. Latin America Growth Hormone Deficiency Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Type, 2020-2034
14.2.1. Therapeutic Treatment
14.2.1.1. Norditropin
14.2.1.2. Genotropin
14.2.1.3. Humatrope
14.2.1.4. Saizen
14.2.1.5. Others (Omnitrope, etc.)
14.2.2. Recombinant Human Growth Hormone
14.2.3. Human Pituitary Gland Extracts
14.2.4. Surgery
14.3. Market Attractiveness, by Treatment Type
14.4. Market Value Forecast, by Disease Indication, 2020-2034
14.4.1. Pediatric Growth Hormone Deficiency
14.4.2. Idiopathic Short Stature
14.4.3. Small for Gestational Age
14.4.4. Turner Syndrome
14.4.5. Adult Growth Hormone Deficiency
14.4.6. Others (Prader-Willi Syndrome, etc.)
14.5. Market Attractiveness, by Disease Indication
14.6. Market Value Forecast, by Route of Administration, 2020-2034
14.6.1. Subcutaneous
14.6.2. Intramuscular
14.6.3. Intravenous
14.7. Market Attractiveness, by Route of Administration
14.8. Market Value Forecast, by Distribution Channel, 2020-2034
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Treatment Type
14.11.2. By Disease Indication
14.11.3. By Route of Administration
14.11.4. By Distribution Channel
14.11.5. By Country/Sub-region
15. Middle East & Africa Growth Hormone Deficiency Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment Type, 2020-2034
15.2.1. Therapeutic Treatment
15.2.1.1. Norditropin
15.2.1.2. Genotropin
15.2.1.3. Humatrope
15.2.1.4. Saizen
15.2.1.5. Others (Omnitrope, etc.)
15.2.2. Recombinant Human Growth Hormone
15.2.3. Human Pituitary Gland Extracts
15.2.4. Surgery
15.3. Market Attractiveness, by Treatment Type
15.4. Market Value Forecast, by Disease Indication, 2020-2034
15.4.1. Pediatric Growth Hormone Deficiency
15.4.2. Idiopathic Short Stature
15.4.3. Small for Gestational Age
15.4.4. Turner Syndrome
15.4.5. Adult Growth Hormone Deficiency
15.4.6. Others (Prader-Willi Syndrome, etc.)
15.5. Market Attractiveness, by Disease Indication
15.6. Market Value Forecast, by Route of Administration, 2020-2034
15.6.1. Subcutaneous
15.6.2. Intramuscular
15.6.3. Intravenous
15.7. Market Attractiveness, by Route of Administration
15.8. Market Value Forecast, by Distribution Channel, 2020-2034
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Treatment Type
15.11.2. By Disease Indication
15.11.3. By Route of Administration
15.11.4. By Distribution Channel
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Novo Nordisk A/S
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Pfizer Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Merck KGaA
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Eli Lilly and Company
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Novartis AG
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. F. Hoffmann-La Roche AG
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Ipsen Pharma
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Ferring Pharmaceuticals
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Anhui Anke Biotechnology (Group) Co., Ltd.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Zhongshan Sinobioway Hygene Biomedicine Co., Ltd.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Others
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
List of Tables
Table 01: Global Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 02: Global Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 03: Global Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 04: Global Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 05: Global Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 06: North America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 07: North America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 08: North America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 9: North America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 10: North America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 11: Europe Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 12: Europe Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 13: Europe Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 14: Europe Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 15: Europe Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 16: Asia Pacific Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Asia Pacific Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 18: Asia Pacific Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 19: Asia Pacific Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 20: Asia Pacific Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 21: Latin America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Latin America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 23: Latin America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 24: Latin America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 25: Latin America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
Table 26: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 27: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 28: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034
Table 29: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 30: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
List of Figures
Figure 01: Global Growth Hormone Deficiency Market Size (US$ Bn), by Region, 2023 and 2034
Figure 02: Global Growth Hormone Deficiency Market Revenue (US$ Bn), by Treatment Type, 2023
Figure 03: Global Growth Hormone Deficiency Market Value Share, by Treatment Type, 2023
Figure 04: Global Growth Hormone Deficiency Market Revenue (US$ Bn), by Disease Indication, 2023
Figure 05: Global Growth Hormone Deficiency Market Value Share, by Disease Indication, 2023
Figure 06: Global Growth Hormone Deficiency Market Revenue (US$ Bn), by Route of Administration, 2023
Figure 07: Global Growth Hormone Deficiency Market Value Share, by Route of Administration, 2023
Figure 08: Global Growth Hormone Deficiency Market Revenue (US$ Bn), by Distribution Channel, 2023
Figure 09: Global Growth Hormone Deficiency Market Value Share, by Distribution Channel, 2023
Figure 10: Global Growth Hormone Deficiency Market Value Share, by Region, 2023
Figure 11: Global Growth Hormone Deficiency Market Value (US$ Bn) Forecast, 2020-2034
Figure 12: Global Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 13: Global Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 14: Global Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 15: Global Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 16: Global Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 17: Global Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 18: Global Growth Hormone Deficiency Market Revenue (US$ Bn), by Distribution Channel, 2023
Figure 19: Global Growth Hormone Deficiency Market Value Share, by Distribution Channel, 2023
Figure 20: Global Growth Hormone Deficiency Market Value Share Analysis, by Region, 2023 and 2034
Figure 21: Global Growth Hormone Deficiency Market Attractiveness Analysis, by Region, 2024-2034
Figure 22: North America Growth Hormone Deficiency Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 23: North America Growth Hormone Deficiency Market Attractiveness Analysis, by Country, 2024-2034
Figure 24: North America Growth Hormone Deficiency Market Value Share Analysis, by Country, 2023 and 2034
Figure 25: North America Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 26: North America Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 27: North America Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 28: North America Growth Hormone Deficiency Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 29: North America Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 30: North America Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 31: North America Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 32: North America Growth Hormone Deficiency Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 33: Europe Growth Hormone Deficiency Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 34: Europe Growth Hormone Deficiency Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 35: Europe Growth Hormone Deficiency Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 36: Europe Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 37: Europe Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 38: Europe Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 39: Europe Growth Hormone Deficiency Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 40: Europe Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 41: Europe Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 42: Europe Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 43: Europe Growth Hormone Deficiency Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 44: Asia Pacific Growth Hormone Deficiency Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 45: Asia Pacific Growth Hormone Deficiency Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 46: Asia Pacific Growth Hormone Deficiency Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 47: Asia Pacific Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 48: Asia Pacific Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 49: Asia Pacific Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 50: Asia Pacific Growth Hormone Deficiency Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 51: Asia Pacific Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 52: Asia Pacific Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 53: Asia Pacific Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 54: Asia Pacific Growth Hormone Deficiency Market Attractiveness Analysis, by Distribution Channel, 2023–2034
Figure 55: Latin America Growth Hormone Deficiency Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 56: Latin America Growth Hormone Deficiency Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 57: Latin America Growth Hormone Deficiency Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 58: Latin America Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 59: Latin America Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 60: Latin America Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 61: Latin America Growth Hormone Deficiency Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 62: Latin America Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 63: Latin America Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 64: Latin America Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 65: Latin America Growth Hormone Deficiency Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Figure 66: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 67: Middle East & Africa Growth Hormone Deficiency Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 68: Middle East & Africa Growth Hormone Deficiency Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 69: Middle East & Africa Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 70: Middle East & Africa Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034
Figure 71: Middle East & Africa Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 72: Middle East & Africa Growth Hormone Deficiency Market Value Share Analysis, by Distribution Channel, 2023 and 2034
Figure 73: Middle East & Africa Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034
Figure 74: Middle East & Africa Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034
Figure 75: Middle East & Africa Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 76: Middle East & Africa Growth Hormone Deficiency Market Attractiveness Analysis, by Distribution Channel, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Growth Hormone Deficiency Market
